Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …

Several studies have shown that interleukin 6 (IL-6) is a multifunctional cytokine with both
pro-inflammatory and anti-inflammatory activity, depending on the immune response …

Abstract During SARS-CoV-2 infection, the innate immune response can be inhibited or
delayed, and the subsequent persistent viral replication can induce emergency signals that …

Background Randomized controlled trials (RCT) established the mortality reduction by
tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID …

Despite global vaccination programs, infections with severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) continue to cause severe disease with significant morbidity …

Background Our objective was to determine whether anti-interleukin (IL)-6 receptors
improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to
global health for nearly 3 years. In addition to pulmonary complications, liver injury is not …

Two years have passed since WHO declared a pandemic state for SARS-CoV-2 infection.
COVID-19 pathogenesis consists of a first viral phase responsible for early symptoms …

Abstract Objective Trials within Cohorts (TwiCs) is a pragmatic design approach that may
overcome frequent challenges of traditional randomized trials such as slow recruitment …

Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be
classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers …